HUP0003844A2 - Új spiroazabiciklikus heterociklusos vegyületek, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények - Google Patents

Új spiroazabiciklikus heterociklusos vegyületek, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0003844A2
HUP0003844A2 HU0003844A HUP0003844A HUP0003844A2 HU P0003844 A2 HUP0003844 A2 HU P0003844A2 HU 0003844 A HU0003844 A HU 0003844A HU P0003844 A HUP0003844 A HU P0003844A HU P0003844 A2 HUP0003844 A2 HU P0003844A2
Authority
HU
Hungary
Prior art keywords
atom
group
active ingredients
optionally substituted
well
Prior art date
Application number
HU0003844A
Other languages
English (en)
Inventor
Robert Mack
John Macor
Eifion Phillips
Simon Semus
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9702746A external-priority patent/SE9702746D0/xx
Priority claimed from SE9800977A external-priority patent/SE9800977D0/xx
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of HUP0003844A2 publication Critical patent/HUP0003844A2/hu
Publication of HUP0003844A3 publication Critical patent/HUP0003844A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány tárgyát az általános képletű vegyületek - ahol n, m és p = 0 vagy 1; Y metincsoport, nitrogénatom vagy <N<Oképletű csoport; X oxigén- vagy kénatom; W oxigénatom vagy kéthidrogén- vagy fluoratom; A, G és D adott esetben alkil-, alkenil-,alkinil-, aril-, heteroaril-, hidroxi-, alkoxi-, karboxi-, alkoxi-karbonil-, ciano-, nitro-, adott esetben szubsztituált vagy ciklusosamino-, trifluor-metil- vagy[(trifluor-metil)-szulfonil]-oxi-csoporttal szubsztituált (beleértve az A és G, illetve G és Dtalálkozási pontokra épített 6-tagú aromás vagy heteroaromás, adottesetben szubsztituált, kondenzált gyűrűket is) metincsoport, vagy egyközülük nitrogénatom - és enantiomereik, valamint sóik, ezekethatóanyagként tartalmazó gyógyszerkészítmények és gyógyászatialkalmazásuk, a hatóanyagok előállítására szolgáló eljárás (ami amegfelelő N-borán-komplex savval vagy alkoholos oldószerbenmelegítéssel végzett bontásából áll), továbbá az intermedier N-borán-komplexek képezik. A találmány szerinti vegyületek a nikotin típusúacetilkolinreceptorok (nAChR'S) ligandumai, alkalmazhatók a csökkentkolinerg működéssel kapcsolatos betegségek kezelésére. Ó
HU0003844A 1997-07-18 1998-07-10 Novel spiroazabicyclic heterocyclic compounds, process for their preparation, their use and pharmaceutical compositions containing them HUP0003844A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702746A SE9702746D0 (sv) 1997-07-18 1997-07-18 New compounds
SE9800977A SE9800977D0 (sv) 1998-03-24 1998-03-24 New compounds
PCT/SE1998/001364 WO1999003859A1 (en) 1997-07-18 1998-07-10 Novel spiroazabicyclic heterocyclic compounds

Publications (2)

Publication Number Publication Date
HUP0003844A2 true HUP0003844A2 (hu) 2001-07-30
HUP0003844A3 HUP0003844A3 (en) 2002-11-28

Family

ID=26663041

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003844A HUP0003844A3 (en) 1997-07-18 1998-07-10 Novel spiroazabicyclic heterocyclic compounds, process for their preparation, their use and pharmaceutical compositions containing them

Country Status (31)

Country Link
US (6) US6110914A (hu)
EP (2) EP0996622B1 (hu)
JP (1) JP2001510194A (hu)
KR (1) KR100560036B1 (hu)
CN (1) CN1117755C (hu)
AR (2) AR013184A1 (hu)
AT (2) ATE283859T1 (hu)
AU (1) AU739022B2 (hu)
BR (1) BR9810924A (hu)
CA (1) CA2296031C (hu)
DE (2) DE69827977T2 (hu)
DK (1) DK0996622T3 (hu)
EE (1) EE04399B1 (hu)
ES (2) ES2185185T3 (hu)
HK (3) HK1025322A1 (hu)
HU (1) HUP0003844A3 (hu)
ID (1) ID25548A (hu)
IL (2) IL134086A0 (hu)
IS (2) IS2027B (hu)
MY (1) MY116761A (hu)
NO (1) NO325324B1 (hu)
NZ (1) NZ502298A (hu)
PL (1) PL193065B1 (hu)
PT (1) PT996622E (hu)
RU (1) RU2202553C2 (hu)
SA (1) SA98190668B1 (hu)
SI (1) SI0996622T1 (hu)
SK (1) SK283484B6 (hu)
TR (1) TR200000129T2 (hu)
TW (1) TW515799B (hu)
WO (1) WO1999003859A1 (hu)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69819891T2 (de) 1997-05-30 2004-08-26 Neurosearch A/S Spiro chinuclidin-derivate, ihre herstellung und verwendung
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
TWI298068B (en) * 2000-06-21 2008-06-21 Dainippon Sumitomo Pharma Co Pharmaceutical composition for schizophrenia
MXPA03010996A (es) * 2001-06-01 2004-02-27 Aztrazeneca Ab Nuevo ligando para receptores nicotinicos de acetilcolina utiles en terapia.
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
EP1453828A2 (en) * 2001-10-16 2004-09-08 AstraZeneca AB Azabicyclic compounds for the treatment of fibromyalgia syndrome
CA2470567A1 (en) 2001-12-14 2003-06-26 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
ES2326638T3 (es) 2002-04-18 2009-10-16 Astrazeneca Ab Compuestos heterociclicos.
MXPA04010193A (es) * 2002-04-18 2005-02-03 Astrazeneca Ab Compuesto de tienilo.
JP4511195B2 (ja) * 2002-04-18 2010-07-28 アストラゼネカ・アクチエボラーグ フリル化合物
JP4667867B2 (ja) 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
ATE378048T1 (de) * 2002-12-06 2007-11-15 The Feinstein Inst Medical Res Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
EP1598355A4 (en) * 2003-01-08 2010-01-27 Mitsubishi Tanabe Pharma Corp THERAPEUTIC AGENT FOR SCHIZOPHRENIA
WO2005000250A2 (en) * 2003-06-24 2005-01-06 Johns Hopkins University Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor
CN1856497A (zh) 2003-09-25 2006-11-01 阿斯利康(瑞典)有限公司 配体
WO2005037832A2 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
US7544693B2 (en) * 2003-10-21 2009-06-09 Astrazeneca Ab Spirofuropyridine aryl derivatives
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
EP1734941A2 (en) * 2004-03-25 2006-12-27 The Feinstein Institute for Medical Research Neural tourniquet
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
DE602005025020D1 (de) 2004-12-27 2011-01-05 The Feinstein Inst Medical Res Behandlung von entzündlichen erkrankungen durch el
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
KR20080035649A (ko) 2005-08-22 2008-04-23 타가셉트 인코포레이티드 헤테로아릴로 치환된 디아자트리시클로알칸, 그 제조방법및 용도
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
US20080242688A1 (en) * 2007-03-19 2008-10-02 Astrazeneca Ab Method 741
JP2010523587A (ja) 2007-04-02 2010-07-15 パーキンソンズ インスティテュート 治療処置の副作用の低減のための方法および組成物
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US8114891B2 (en) 2007-10-01 2012-02-14 Comentis, Inc. 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof
BRPI0907570A2 (pt) 2008-02-13 2019-09-24 Targacept Inc agonistas alfa7 nicotínico e antipsicóticos
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
CN102131791B (zh) 2008-06-20 2014-12-24 阿斯利康(瑞典)有限公司 二苯并硫杂氮杂*衍生物及其用途
AU2009316801C1 (en) 2008-11-18 2015-12-24 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflammatory stimulation
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8612002B2 (en) 2009-12-23 2013-12-17 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
CA2778673A1 (en) 2009-10-27 2011-05-05 Karen Margrete Miller Function modifying nav 1.7 antibodies
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
EP2571874B1 (en) 2010-05-17 2016-03-30 Forum Pharmaceuticals Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
CN103619405B (zh) 2011-05-09 2015-11-25 赛博恩特医疗器械公司 用于治疗慢性炎症的胆碱能抗炎通路的单个脉冲激活
RU2455306C1 (ru) * 2011-05-19 2012-07-10 Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 3',4',5,6-ТЕТРАГИДРО-1Н-СПИРО[ПИРИДИН-4,5'-ТИЕНО[2,3-d]ПИРИМИДИНОВ]
KR20140027939A (ko) 2011-06-30 2014-03-07 도레이 카부시키가이샤 지양제
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
US8893339B2 (en) 2013-03-14 2014-11-25 Select Comfort Corporation System and method for adjusting settings of a bed with a remote control
AU2014282977B2 (en) 2013-06-21 2018-06-14 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20170166561A1 (en) 2014-07-11 2017-06-15 Alpharmagen, Llc Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405255A4 (en) 2016-01-20 2019-10-16 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION RECHARGE SYSTEMS
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
EP3856180A1 (en) 2018-09-24 2021-08-04 Astrazeneca AB Azd0328 dosage regime for treating cognitive impairment
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
IL298193B2 (en) 2020-05-21 2024-01-01 Feinstein Institutes For Medical Research Systems and methods for stimulating the vagus nerve
CN115340736B (zh) * 2022-05-20 2023-09-29 扬州实嘉电缆材料有限公司 一种氮磷阻燃剂改性聚氯乙烯防火电缆料

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681363A (en) * 1970-08-20 1972-08-01 Univ Temple Spiro(imidazolidine-4,3{40 -quinuclidine)-2,5-diones
WO1996006098A1 (en) * 1994-08-24 1996-02-29 Astra Aktiebolag Spiro-azabicyclic compounds useful in therapy
US5468875A (en) * 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives
JP4176147B2 (ja) * 1995-07-28 2008-11-05 アボツト・ラボラトリーズ 化学的シナプス伝達の制御に有用なフロピリジン、チエノピリジン、ピロロピリジンおよび関連するピリミジン、ピリダジンおよびトリアジン化合物
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis

Also Published As

Publication number Publication date
NO325324B1 (no) 2008-03-31
AU8367998A (en) 1999-02-10
HK1046274B (zh) 2005-05-20
AR068013A2 (es) 2009-10-28
TW515799B (en) 2003-01-01
IS2027B (is) 2005-08-15
IS7747A (is) 2005-03-16
US6369224B1 (en) 2002-04-09
NZ502298A (en) 2002-02-01
HUP0003844A3 (en) 2002-11-28
ATE283859T1 (de) 2004-12-15
PL338259A1 (en) 2000-10-09
DE69827977T2 (de) 2005-12-08
TR200000129T2 (tr) 2000-07-21
DK0996622T3 (da) 2002-12-30
KR100560036B1 (ko) 2006-03-13
HK1046274A1 (en) 2003-01-03
SA98190668B1 (ar) 2006-09-25
ID25548A (id) 2000-10-12
EP1213291B1 (en) 2004-12-01
WO1999003859A1 (en) 1999-01-28
US6703502B2 (en) 2004-03-09
IS2434B (is) 2008-10-15
HK1031382A1 (en) 2001-06-15
PT996622E (pt) 2003-01-31
MY116761A (en) 2004-03-31
EP0996622B1 (en) 2002-10-09
IS5338A (is) 2000-01-13
ES2185185T3 (es) 2003-04-16
KR20010021961A (hu) 2001-03-15
EP1213291A1 (en) 2002-06-12
PL193065B1 (pl) 2007-01-31
EE200000031A (et) 2000-10-16
AU739022B2 (en) 2001-10-04
JP2001510194A (ja) 2001-07-31
BR9810924A (pt) 2000-08-15
EP0996622A1 (en) 2000-05-03
DE69808631D1 (de) 2002-11-14
SK183599A3 (en) 2000-08-14
US6110914A (en) 2000-08-29
US20080153864A1 (en) 2008-06-26
AR013184A1 (es) 2000-12-13
ATE225792T1 (de) 2002-10-15
US20020187994A1 (en) 2002-12-12
DE69808631T2 (de) 2003-06-12
US7507744B2 (en) 2009-03-24
ES2231599T3 (es) 2005-05-16
DE69827977D1 (de) 2005-01-05
NO20000226L (no) 2000-03-14
RU2202553C2 (ru) 2003-04-20
IL134086A0 (en) 2001-04-30
US20050004099A1 (en) 2005-01-06
SK283484B6 (sk) 2003-08-05
NO20000226D0 (no) 2000-01-17
HK1025322A1 (en) 2000-11-10
CA2296031C (en) 2008-01-08
IL134086A (en) 2007-08-19
CA2296031A1 (en) 1999-01-28
US20030166935A1 (en) 2003-09-04
CN1270592A (zh) 2000-10-18
SI0996622T1 (en) 2003-04-30
US6706878B2 (en) 2004-03-16
CN1117755C (zh) 2003-08-13
EE04399B1 (et) 2004-12-15

Similar Documents

Publication Publication Date Title
HUP0003844A2 (hu) Új spiroazabiciklikus heterociklusos vegyületek, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
ATE224888T1 (de) Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
NO854833L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tricykloforbindelser.
FI963294A0 (fi) Naftyyliamidit keskushermostoaineina
HUP0004531A2 (hu) VLA-4 által mediált leukocita adhéziót gátló 4-aminofenilalanin-vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
BR9407910A (pt) Composto composiçao farmacêutica uso do composto processo de tratamento de distúrbios no sistema nervoso central e processo de preparaçao do composto
HUP0500017A2 (hu) Alkil-éter-származékok, sóik és az ezeket tartalmazó gyógyszerkészítmények
FI946073A (fi) Vitamiini D-sarjan, 20-asemassa modifioituja johdannaisia, menetelmä tällaisten johdannaisten valmistamiseksi, menetelmässä käytettäviä välituotteita, mainittuja johdannaisia sisältäviä farmaseuttisia valmisteita ja johdannaisten käyttö lääkeaineiden valmistamiseen
PT89534A (pt) Processo para a preparacao de composicoes farmaceuticas anticoagulantes contendo como ingrediente activo proteina c ou proteina c activada combinada com heparina
DK154208C (da) Analogifremgangsmaade til fremstilling af p-substituerede 3-fenoxy-1-alkylaminopropanoler eller terapeutisk acceptable salte deraf
DE69431476D1 (de) Einschlusskomplexe von taxol oder taxotere oder taxus-extrakten und cyclodextrinen, ihre herstellung und ihre verwendung
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
DK1194415T3 (da) Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling
DE3773017D1 (de) Nicorandil enthaltende zubereitung zum einspritzen.
HUP0003624A2 (hu) 1,2,3,4-Tetrahidro-benzofuro[3,2-c]piridin-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
ATE260252T1 (de) Thiocolchicin-derivate mit entzündungshemmender und muskelrelaxierender wirkung
ATE80613T1 (de) Verwendung von spergualinderivaten zur herstellung von arzneimitteln mit immunodepressiver wirkung.
IE790113L (en) Pyridone carboxylic acid derivatives.
ATE69228T1 (de) Amidabkoemmlinge.
HUP9801713A1 (hu) Heterociklusos gyűrűvel helyettesített imidazolszármazékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények
ES8201169A1 (es) Un procedimiento para la preparacion de derivados de quina- zolina
HUP0400833A2 (hu) Benzo[g]kinolin-származékok glaukoma és miopia kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0004386A2 (hu) Metilén-biszfoszfonsav-származékok, eljárás előállításukra és azokat hatóanyagként tartalmazó gyógyszerkészítmények
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten
FR2438656A1 (hu)

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees